Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial

2021 ◽  
pp. appi.ajp.2020.2
Author(s):  
Jennifer B. Dwyer ◽  
Angeli Landeros-Weisenberger ◽  
Jessica A. Johnson ◽  
Amalia Londono Tobon ◽  
José M. Flores ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Adolescent Treatment ◽  
Resistant Depression ◽  
Intravenous Ketamine

scholarly journals Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial

2020 ◽  
Vol 46 (2) ◽  
pp. 462-469
Author(s):  
Paul E. Croarkin ◽  
Ahmed Z. Elmaadawi ◽  
Scott T. Aaronson ◽  
G. Randolph Schrodt ◽  
Richard C. Holbert ◽  
...  
Keyword(s):  
Transcranial Magnetic Stimulation ◽  
Magnetic Stimulation ◽  
Controlled Trial ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Double Blind ◽  
Resistant Depression

scholarly journals Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

2018 ◽  
Vol 49 (4) ◽  
pp. 655-663 ◽  
Author(s):  
Fernanda Palhano-Fontes ◽  
Dayanna Barreto ◽  
Heloisa Onias ◽  
Katia C. Andrade ◽  
Morgana M. Novaes ◽  
...  
Keyword(s):  
Rating Scale ◽  
Remission Rate ◽  
Controlled Trial ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Open Label ◽  
Double Blind ◽  
Therapeutic Value ◽  
Antidepressant Effects ◽  
Resistant Depression

AbstractBackgroundRecent open-label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression.MethodsTo test the antidepressant effects of ayahuasca, we conducted a parallel-arm, double-blind randomized placebo-controlled trial in 29 patients with treatment-resistant depression. Patients received a single dose of either ayahuasca or placebo. We assessed changes in depression severity with the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Hamilton Depression Rating scale at baseline, and at 1 (D1), 2 (D2), and 7 (D7) days after dosing.ResultsWe observed significant antidepressant effects of ayahuasca when compared with placebo at all-time points. MADRS scores were significantly lower in the ayahuasca group compared with placebo at D1 and D2 (p= 0.04), and at D7 (p< 0.0001). Between-group effect sizes increased from D1 to D7 (D1: Cohen'sd= 0.84; D2: Cohen'sd= 0.84; D7: Cohen'sd= 1.49). Response rates were high for both groups at D1 and D2, and significantly higher in the ayahuasca group at D7 (64%v.27%;p= 0.04). Remission rate showed a trend toward significance at D7 (36%v.7%,p= 0.054).ConclusionsTo our knowledge, this is the first controlled trial to test a psychedelic substance in treatment-resistant depression. Overall, this study brings new evidence supporting the safety and therapeutic value of ayahuasca, dosed within an appropriate setting, to help treat depression. This study is registered athttp://clinicaltrials.gov(NCT02914769).

scholarly journals Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study

2018 ◽  
Vol 28 (7) ◽  
pp. 437-444 ◽  
Author(s):  
Kathryn R. Cullen ◽  
Palistha Amatya ◽  
Mark G. Roback ◽  
Christina Sophia Albott ◽  
Melinda Westlund Schreiner ◽  
...  
Keyword(s):  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Resistant Depression ◽  
Intravenous Ketamine

scholarly journals Mindfulness-based cognitive therapy for patients with chronic, treatment-resistant depression: A pragmatic randomized controlled trial

2018 ◽  
Vol 35 (10) ◽  
pp. 914-924 ◽  
Author(s):  
Mira B. Cladder-Micus ◽  
Anne E.M. Speckens ◽  
Janna N. Vrijsen ◽  
A. Rogier T. Donders ◽  
Eni S. Becker ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Cognitive Therapy ◽  
Chronic Treatment ◽  
Controlled Trial ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Pragmatic Randomized Controlled Trial ◽  
Randomized Controlled ◽  
Resistant Depression

scholarly journals Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Sanne Y. Smith-Apeldoorn ◽  
Jolien K. E. Veraart ◽  
Jeanine Kamphuis ◽  
Antoinette D. I. van Asselt ◽  
Daan J. Touw ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Treatment Strategies ◽  
Repeated Administration ◽  
Additional Treatment ◽  
Racemic Mixture ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Routes Of Administration ◽  
Antidepressant Efficacy ◽  
Resistant Depression

Abstract Background There is an urgent need to develop additional treatment strategies for patients with treatment-resistant depression (TRD). The rapid but short-lived antidepressant effects of intravenous (IV) ketamine as a racemic mixture have been shown repeatedly in this population, but there is still a paucity of data on the efficacy and safety of (a) different routes of administration, and (b) ketamine’s enantiomers esketamine and arketamine. Given practical advantages of oral over IV administration and pharmacodynamic arguments for better antidepressant efficacy of esketamine over arketamine, we designed a study to investigate repeated administration of oral esketamine in patients with TRD. Methods This study features a triple-blind randomized placebo-controlled trial (RCT) comparing daily oral esketamine versus placebo as add-on to regular antidepressant medications for a period of 6 weeks, succeeded by a follow-up of 4 weeks. The methods support examination of the efficacy, safety, tolerability, mechanisms of action, and economic impact of oral esketamine in patients with TRD. Discussion This is the first RCT investigating repeated oral esketamine administration in patients with TRD. If shown to be effective and tolerated, oral esketamine administration poses important advantages over IV administration. Trial registration Dutch Trial Register, NTR6161. Registered 21 October 2016.

Sign in / Sign up

Export Citation Format

Share Document